A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

NCT07389616 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Cidabenamine, Azacitidine

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine